# Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

> **NCT04683848** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Spinal Cord Injury

## Interventions

- **BIOLOGICAL:** MT-3921
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04683848
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-27
- **Primary completion:** 2024-12-24
- **Final completion:** 2025-04-09
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04683848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04683848, "Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04683848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*